…
Reckitt Benckiser Group plc manufactures and sells health, hygiene, and nutrition products in the United Kingdom and internationally. The company offers germ protection under Dettol name; intimate wellness under Durex and KY brand names; over the counter under the Biofreeze, Gaviscon, Mucinex, Nurofen, Delsym, Cepacol, and Strepsils names. It also provides personal care products under Clearasil and Veet brand names; vitamins, minerals, and supplements under MegaRed, Airborne, Digestive-Advantage, Movefree, and neuriva names; stain removal under Vanish brand name; and disinfectant products under the Finish, Harpic, and Lysol brands. In addition, the company offers nutritious complementary foods and milk formulas for infant and young children under the Enfamil and Nutramigen brands. Reckitt Benckiser Group plc was founded in 1819 and is headquartered in Slough, the United Kingdom.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | 3838.00M | 2104.00M | 2401.00M | 3067.00M | -260.00M |
| Minority interest | -5.00M | -2.00M | -14.00M | -19.00M | -11.00M |
| Net income | 3182.00M | 1426.00M | 1643.00M | 2330.00M | -52.00M |
| Selling general administrative | 4892.00M | 1294.00M | 1382.00M | 1205.00M | 1190.00M |
| Selling and marketing expenses | - | 3537.00M | 3703.00M | 3438.00M | 3460.00M |
| Gross profit | 8634.00M | 8595.00M | 8760.00M | 8361.00M | 7676.00M |
| Reconciled depreciation | 499.00M | 461.00M | 470.00M | 607.00M | 481.00M |
| Ebit | - | 2489.00M | 2719.00M | 3249.00M | 3488.00M |
| Ebitda | 4217.00M | 2950.00M | 3189.00M | 3936.00M | 3969.00M |
| Depreciation and amortization | - | 461.00M | 470.00M | 687.00M | 481.00M |
| Operating income | 4217.00M | 2425.00M | 2531.00M | 3249.00M | 3488.00M |
| Other operating expenses | 9988.00M | 11744.00M | 12076.00M | 11218.00M | 10520.00M |
| Interest expense | 395.00M | 385.00M | 318.00M | 257.00M | 244.00M |
| Tax provision | 635.00M | 672.00M | 753.00M | 711.00M | -208.00M |
| Interest income | 41.00M | 53.00M | 41.00M | 127.00M | 29.00M |
| Net interest income | -379.00M | -321.00M | -289.00M | -230.00M | -233.00M |
| Extraordinary items | - | - | - | -7.00M | 31.00M |
| Income tax expense | 635.00M | 672.00M | 753.00M | 711.00M | -208.00M |
| Total revenue | 14205.00M | 14169.00M | 14607.00M | 14453.00M | 13234.00M |
| Total operating expenses | 4417.00M | 6170.00M | 6229.00M | 5126.00M | 4962.00M |
| Cost of revenue | 5571.00M | 5574.00M | 5847.00M | 6092.00M | 5558.00M |
| Total other income expense net | -379.00M | -321.00M | -130.00M | -182.00M | -3748.00M |
| Discontinued operations | - | - | - | -7.00M | 31.00M |
| Net income from continuing ops | 3203.00M | 1432.00M | 1648.00M | 2356.00M | -52.00M |
| Net income applicable to common shares | - | - | - | 2330.00M | -32.00M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2023-06-30 | 2022-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2023-06-30 | 2022-12-31 |
| Total assets | 25068.00M | 25298.00M | 27136.00M | - | 28742.00M |
| Intangible assets | 12078.00M | 13744.00M | 14010.00M | - | 14594.00M |
| Other current assets | 28.00M | 230.00M | 573.00M | - | 2303.00M |
| Total liab | 17287.00M | 18578.00M | 18667.00M | - | 19259.00M |
| Total stockholder equity | 7746.00M | 6699.00M | 8448.00M | - | 9443.00M |
| Other current liab | 768.00M | 3489.00M | 3723.00M | - | 1073.00M |
| Common stock | 70.00M | 74.00M | 74.00M | - | 74.00M |
| Capital stock | 70.00M | 74.00M | 74.00M | - | 74.00M |
| Retained earnings | 9170.00M | 21990.00M | 23409.00M | - | 23638.00M |
| Other liab | - | - | - | - | 3755.00M |
| Good will | 3733.00M | 3821.00M | 4578.00M | - | 5609.00M |
| Other assets | - | - | - | - | 538.00M |
| Cash | 1952.00M | 760.00M | 1387.00M | - | 1157.00M |
| Cash and equivalents | - | - | - | - | 1157.00M |
| Total current liabilities | 6650.00M | 7943.00M | 8338.00M | - | 8341.00M |
| Current deferred revenue | - | - | 620.00M | - | - |
| Net debt | 6478.00M | 7898.00M | 7150.00M | - | 7727.00M |
| Short term debt | 810.00M | 1423.00M | 1679.00M | - | 1721.00M |
| Short long term debt | 745.00M | 1344.00M | 1601.00M | - | 1643.00M |
| Short long term debt total | 8430.00M | 8658.00M | 8537.00M | - | 8884.00M |
| Other stockholder equity | -1498.00M | -15365.00M | -13975.00M | - | -14269.00M |
| Property plant equipment | - | - | - | - | 2473.00M |
| Total current assets | 5635.00M | 4598.00M | 5302.00M | - | 5285.00M |
| Net tangible assets | - | - | - | - | -10760.00M |
| Short term investments | - | - | 122.00M | - | - |
| Net receivables | 2182.00M | 2091.00M | 1705.00M | - | 2082.00M |
| Long term debt | 7411.00M | 7014.00M | 6609.00M | - | 6852.00M |
| Inventory | 1473.00M | 1517.00M | 1637.00M | - | 1825.00M |
| Accounts payable | 5072.00M | 2268.00M | 2194.00M | - | 5547.00M |
| Accumulated other comprehensive income | 4.00M | -1390.00M | -1060.00M | - | - |
| Non currrent assets other | 284.00M | 399.00M | 442.00M | - | 537.00M |
| Non current assets total | 19433.00M | 20700.00M | 21834.00M | - | 23457.00M |
| Capital lease obligations | 274.00M | 300.00M | 327.00M | - | 389.00M |
| Long term debt total | - | - | - | - | 7163.00M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | - | -396.00M | -466.00M | -139.00M | -27.00M |
| Change to liabilities | - | - | - | -145.00M | -126.00M |
| Total cashflows from investing activities | 1195.00M | -396.00M | -466.00M | -139.00M | 239.00M |
| Net borrowings | -225.00M | 81.00M | -217.00M | -1533.00M | -1006.00M |
| Total cash from financing activities | -2433.00M | -2715.00M | -1809.00M | -2380.00M | -2286.00M |
| Net income | 3198.00M | 2104.00M | 1643.00M | 3067.00M | -804.00M |
| Change in cash | 1072.00M | -501.00M | 224.00M | -103.00M | -385.00M |
| Begin period cash flow | 880.00M | 1380.00M | 1156.00M | 1259.00M | 1644.00M |
| End period cash flow | 1952.00M | 879.00M | 1380.00M | 1156.00M | 1259.00M |
| Total cash from operating activities | 2297.00M | 2682.00M | 2636.00M | 2397.00M | 1697.00M |
| Issuance of capital stock | 40.00M | 0.00M | 46.00M | 54.00M | 80.00M |
| Depreciation | 499.00M | 461.00M | 470.00M | 607.00M | 481.00M |
| Other cashflows from investing activities | 1.00M | -26.00M | -37.00M | 304.00M | 689.00M |
| Dividends paid | 1403.00M | 1381.00M | 1339.00M | 1249.00M | 1246.00M |
| Change to inventory | -196.00M | 61.00M | 118.00M | -254.00M | -57.00M |
| Change to account receivables | - | -133.00M | -87.00M | -23.00M | -130.00M |
| Sale purchase of stock | -879.00M | -1328.00M | -209.00M | 54.00M | -5.00M |
| Other cashflows from financing activities | -191.00M | -87.00M | -92.00M | 2622.00M | -71.00M |
| Change to netincome | - | - | - | 52.00M | 1561.00M |
| Capital expenditures | 536.00M | 465.00M | 449.00M | 443.00M | 450.00M |
| Change in working capital | -328.00M | -146.00M | -60.00M | -422.00M | -313.00M |
| Stock based compensation | 101.00M | 85.00M | 102.00M | 78.00M | 30.00M |
| Other non cash items | -573.00M | 178.00M | 481.00M | -933.00M | 2303.00M |
| Free cash flow | 1761.00M | 2217.00M | 2187.00M | 1954.00M | 1247.00M |
Sector: Consumer Defensive Industry: Household & Personal Products
|
Stock Name
|
Change
(GBX) |
Price
(GBX) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| RKT Reckitt Benckiser Group PLC |
-266.00 4.85% |
5218.00 | 10.71 | 15.13 | 2.37 | 4.31 | 2.82 | 8.41 |
| ULVR Unilever PLC |
-30.50 0.62% |
4892.50 | 19.06 | 15.41 | 1.86 | 6.73 | 2.51 | 11.39 |
| PZC PZ Cussons PLC |
-0.60 0.63% |
95.00 | - | 9.64 | 0.63 | 1.42 | 0.81 | 7.05 |
| TBTG The Beauty Tech Group PLC |
1.00 0.21% |
487.00 | 54.42 | 10.70 | 2.67 | 598.72 | 3.11 | 14.60 |
| MCB McBride plc |
-5.00 2.78% |
175.00 | 9.13 | 5.83 | 0.29 | 2.67 | 0.41 | 4.90 |
Reckitt Benckiser Group plc manufactures and sells health, hygiene, and nutrition products in the United Kingdom and internationally. The company offers germ protection under Dettol name; intimate wellness under Durex and KY brand names; over the counter under the Biofreeze, Gaviscon, Mucinex, Nurofen, Delsym, Cepacol, and Strepsils names. It also provides personal care products under Clearasil and Veet brand names; vitamins, minerals, and supplements under MegaRed, Airborne, Digestive-Advantage, Movefree, and neuriva names; stain removal under Vanish brand name; and disinfectant products under the Finish, Harpic, and Lysol brands. In addition, the company offers nutritious complementary foods and milk formulas for infant and young children under the Enfamil and Nutramigen brands. Reckitt Benckiser Group plc was founded in 1819 and is headquartered in Slough, the United Kingdom.
| Name | Title | Year Born |
|---|---|---|
| Mr. Nicandro Durante | CEO & Director | 1956 |
| Mr. Jeffrey Carr ACMA, B.Eng | Group CFO & Exec. Director | 1961 |
| Mr. Filippo Catalano | Chief Information & Digitisation Officer | NA |
| Mr. Richard Joyce | Head of Investor Relations | NA |
| Ms. Catheryn O'Rourke | Sr. VP, Gen. Counsel & Company Sec. | NA |
| Mr. Fabrice Beaulieu | Chief Marketing, Sustainability & Corp. Affairs Officer | NA |
| Mr. Ranjay Radhakrishnan | Chief HR Officer | NA |
| Mr. Kris Licht | Pres of Health & Chief Customer Officer | NA |
| Mr. John Dawson | Sr. VP of Investor Relations | NA |
| Mr. Sami Naffakh | Chief Supply Officer | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.